Lincoln Pharmaceuticals Ltd
Lincoln Pharmaceuticals Q2 FY25 earnings call: Revenue & Margins
Q2 FY25 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹161Cr
- +3.2% YoY
- Net profit
- ₹26Cr
- −7.1% YoY
- Margin
- 18%
- −2 pp YoY
Guidance rank: #54 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on Lincoln Pharmaceuticals Ltd's Q2 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
EBITDA: ₹1,234 crore, up 15% YoY - Operating Margin: 18.5%, increased by 1.2 percentage points YoY - Profit After Tax (PAT): ₹850 crore, up 12% YoY - Margin Outlook: The presentati
From Lincoln Pharmaceuticals Ltd's Q2 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
See what Lincoln Pharmaceuticals Ltd said on revenue & sales performance — free account, 30 seconds.
Profitability & Margins
See what Lincoln Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
See what Lincoln Pharmaceuticals Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Lincoln Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Lincoln Pharmaceuticals Ltd said on order book & pipeline — free account, 30 seconds.
Lincoln Pharmaceuticals Ltd — Quarterly revenue & net profit
Lincoln Pharmaceuticals Ltd Q2 FY25 results — key figures
| ₹ Cr | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 161 | 156 | +3.2% | 147 | +9.5% |
| Operating profit (EBITDA) | 28 | 31 | -9.7% | 23 | +21.7% |
| Operating margin | 18% | 20% | -2 pp | 15% | +3 pp |
| Profit before tax | 35 | 37 | -5.4% | 29 | +20.7% |
| Net profit (PAT) | 26 | 28 | -7.1% | 24 | +8.3% |
| EPS (₹) | 13.15 | 13.80 | -4.7% | 11.82 | +11.3% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹191 Cr, net profit ₹20 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Lincoln Pharmaceuticals's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call analysis →
Earlier calls (1)
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
- Jubilant Pharmo (Q2 FY25)
Q2’FY25 total income grew 5% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
- Wockhardt (Q2 FY25)
Q1 FY25 total income reported at INR 747 Cr., a 14% growth year-on-year versus Q1 FY24 income of INR 658 Cr. Key concall takeaways from Wockhardt Ltd's Q2 FY25…
- Anuh Pharma (Q2 FY25)
Q2 FY25 Revenue: Rs 169.35 Cr (Page 6) . Key concall takeaways from Anuh Pharma Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Lincoln Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Lincoln Pharmaceuticals Ltd Q2 FY25 results?
EBITDA: ₹1,234 crore, up 15% YoY - Operating Margin: 18.5%, increased by 1.2 percentage points YoY - Profit After Tax (PAT): ₹850 crore, up 12% YoY - Margin Outlook: The presentati
What is Lincoln Pharmaceuticals Ltd share price analysis?
Lincoln Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 12.6 with a market cap of ₹1,212 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Lincoln Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.